Parion Sciences
“Ray (Hemera) had an immediate impact taking over the back office financial duties during a time of transition for our company. Ray handled everything thrown at him with ease. From corporate financing to community service, Ray is dynamic and proactive, constantly driven to improve any activity he is associated with. His team-focused and detail-oriented approach was instrumental in our company’s successful 2015 fundraising. I would highly recommend Ray to everyone looking for an efficient, personable and well-rounded finance consultant.”
Paul Boucher, MBA
President & CEO
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the lung or eye. Parion has received grant funding from the National Institutes of Health and continues to have a long-standing and valued relationship with Cystic Fibrosis Foundation Therapeutics, Inc. Parion received an $80 million upfront payment as part of an agreement to collaborate with Vertex Pharmaceuticals.